Newsroom
Top Results
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
PDF Version Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused […]
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
PDF Version Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes MENLO PARK, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology […]
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
PDF Version MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced third quarter 2023 revenue guidance and updated its revenue guidance for full year […]
Sight Sciences Appoints Matt Link as Chief Commercial Officer
PDF Version Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ […]
Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
PDF Version MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference […]
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
PDF Version MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance […]
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
PDF Version MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2023, after the market close on […]
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye PDF Version Dry eye has significant negative impact on visual function including reading, driving, workplace productivity, physical functioning, and quality of life, and […]